{
    "clinical_study": {
        "@rank": "51780", 
        "arm_group": [
            {
                "arm_group_label": "EVARREST\u2122", 
                "arm_group_type": "Experimental", 
                "description": "EVARREST\u2122 Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts\u2014 a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin)."
            }, 
            {
                "arm_group_label": "Topical hemostat", 
                "arm_group_type": "Active Comparator", 
                "description": "Equine collagen with Human Fibrinogen and Human Thrombin"
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "arm_group_type": "Active Comparator", 
                "description": "SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a three-arm, randomized multicenter study evaluating the safety and effectiveness of\n      EVARREST\u2122 Fibrin Sealant Patch in controlling mild to moderate vascular anastomosis suture\n      line bleeding in cardiovascular surgery."
        }, 
        "brief_title": "The Fibrin Pad Cardiovascular Study", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Cardiovascular Disease", 
        "condition_browse": {
            "mesh_term": "Cardiovascular Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects \u226518 years of age, requiring an elective or urgent, open aortic surgical\n             procedure utilizing cardiopulmonary bypass;\n\n          -  Subjects must be willing to participate in the study and provide written informed\n             consent.\n\n        Exclusion Criteria:\n\n          -  Subjects with known intolerance to blood products or to one of the components of the\n             study product or unwilling to receive blood products;\n\n          -  Exposure to another investigational drug or device in a clinical trial within 30 days\n             prior to surgery or anticipated in the 30 day follow up period after surgery.\n\n          -  Female subjects who are pregnant or nursing."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01681030", 
            "org_study_id": "400-12-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "EVARREST\u2122", 
                "description": "EVARREST\u2122 Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts\u2014 a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).", 
                "intervention_name": "EVARREST\u2122", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Topical hemostat", 
                "description": "Equine collagen with Human Fibrinogen and Human Thrombin", 
                "intervention_name": "Topical hemostat", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "description": "SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical.", 
                "intervention_name": "Standard of Care", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fibrin Tissue Adhesive"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 19, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Indianopolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46260"
                    }, 
                    "name": "Clinical Investigation Site #5"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64111"
                    }, 
                    "name": "Clinical Investigation Site #6"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Camden", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08103"
                    }, 
                    "name": "Clinical Investigation Site #4"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paterson", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07503"
                    }, 
                    "name": "Clinical Investigation Site #1"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "Clinical Investigation Site #3"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10075"
                    }, 
                    "name": "Clinical Investigation Site #2"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Controlled, Comparative Phase II Study Evaluating the Safety and Effectiveness of EVARREST\u2122 Fibrin Sealant Patch as an Adjunct to Hemostasis During Cardiovascular Surgery", 
        "overall_official": {
            "affiliation": "Ethicon, Inc.", 
            "last_name": "Jerome Riebman, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Hemostasis at the TBS at 3-minutes following treatment application and with no re-bleeding requiring treatment at the TBS any time prior to initiation of final chest wall closure. Hemostasis is defined as no detectable bleeding at the TBS.", 
            "measure": "Hemostasis at the Target Bleeding Site (TBS) at 3-minutes following treatment application", 
            "safety_issue": "Yes", 
            "time_frame": "Intraoperative"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01681030"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Ethicon, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ethicon, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}